Drug intelligence / Profile preview

Eribulin, Capecitabine, Gemcitabine, or Vinorelbine

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

This entry refers to a query for four distinct antineoplastic agents: eribulin, capecitabine, gemcitabine, and vinorelbine. Each of these drugs has a unique chemical structure, mechanism of action, and therapeutic indications. Eribulin is a microtubule dynamics inhibitor, capecitabine is an oral fluoropyrimidine carbamate that is converted to 5-fluorouracil, gemcitabine is a nucleoside analog that inhibits DNA synthesis, and vinorelbine is a vinca alkaloid that interferes with microtubule assembly. These drugs are used in the treatment of various cancers.

Brand names: HalavenXelodaGemzarNavelbine

Targets

TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Eribulin, Capecitabine, Gemcitabine, or Vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eribulin, Capecitabine, Gemcitabine, or Vinorelbine.

Explore the full profile